XML 30 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Pay vs Performance Disclosure - USD ($)
2 Months Ended 3 Months Ended 7 Months Ended 12 Months Ended
Jun. 04, 2022
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure              
Pay vs Performance Disclosure, Table      
Summary Compensation Table
Total
Compensation Actually PaidValue of Initial Fixed
$100 Investment
Based On:
Fiscal
Year
Carrie
Eglinton
Manner
($)1
Nancy
Gagliano,
 M.D.
($)2
Stephen
S. Tang,
Ph.D.
($)3
Carrie
Eglinton
Manner
($)4
Nancy
Gagliano,
M.D.
($)4
Stephen
S. Tang,
Ph.D.
($)4
Average
Summary
Compensation
Table Total for
Non-PEO NEOs
($)5
Average
Compensation
Actually Paid
to
Non-PEO NEOs
($)6
Total
Stockholder
Return
($)7
Peer Group
Total
Stockholder
Return
($)8
Net Income
(Loss)
(thousands)
($)9
Total
Revenue
(millions)
($)10
20236,701,767 — — 13,791,592 — — 1,600,748 2,390,906 102.12 106.34 53,655 405.5 
20226,746,923 940,292 2,769,508 6,645,396 347,561 714,651 1,457,621 751,486 60.02 99.31 (17,934)387.5 
2021— — 2,959,781 — — 2,697,616 1,088,815 808,537 108.22 125.43 (22,998)233.7 
2020— — 3,085,421 — — 3,888,690 1,601,825 1,595,129 131.82 130.04 (14,922)171.1 
     
Company Selected Measure Name         TotalRevenue(millions)($)10    
Named Executive Officers, Footnote       During fiscal year 2022, Ms. Eglinton Manner was appointed as our President and CEO effective June 4, 2022. Dr. Gagliano resigned effective June 4, 2022 from her position as the Company’s Interim CEO. During fiscal year 2022, Dr. Gagliano was appointed as our Interim CEO effective April 1, 2022 following Dr. Tang’s termination on March 31, 2022 and resigned from the position effective June 4, 2022. During fiscal years 2022, 2021 and 2020, Dr. Tang served as our President and CEO for all or a portion of the year. Dr. Tang’s employment with the Company as CEO ended on March 31, 2022. Our non-PEO NEOs includes the individuals indicated in the table below for each fiscal year:
YearNon-PEO NEOs
2023Kenneth McGrath, Kathleen Weber
2022Kenneth McGrath, Kathleen Weber, Lisa Nibauer, Agnieszka Gallagher, Scott Gleason
2021Kathleen Weber, Jack Jerrett, Roberto Cuca, Agnieszka Gallagher, Scott Gleason
2020Kathleen Weber, Jack Jerrett, Roberto Cuca, Anthony Zezzo, Lisa Nibauer
     
Peer Group Issuers, Footnote       For the relevant fiscal year, represents the cumulative total shareholder return (TSR) of NASDAQ Health Care Index for the measurement periods ending on December 31 of each of 2023, 2022, 2021, and 2020, respectively.      
Adjustment To PEO Compensation, Footnote       Represents amounts of “compensation actually paid” to each of our CEO’s in each of 2023, 2022, 2021, and 2020 as computed in accordance with Item 402(v) of Regulation S-K, not the actual amount of compensation earned by or paid to each of our CEO’s during fiscal year 2023. The table below reflects the adjustments made from the amounts reported in the “Total” column of the Summary Compensation Table for each year to calculate the amounts set forth in “Compensation Actually Paid to PEO” column in the table above.
Carrie Eglinton MannerNancy Gagliano, M.D.Stephen S. Tang, Ph.D.
2023 ($)2022 ($)2022 ($)2022 ($)
2021 ($)(a)
2020 ($)(a)
Summary Compensation Table Total6,701,767 6,746,923 940,292 2,769,508 2,959,781 3,085,421 
Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year(4,873,637)(5,600,000)(770,000)
(b)
(834,913)(1,946,860)(1,218,000)
Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year8,377,123 5,498,473 — — 1,337,758 1,799,376 
Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years3,488,559 — (40,879)— 132,795 237,531 
Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year— — 218,148 664,350 — — 
Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year97,780 — — (1,387,479)214,142 (15,638)
Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year— — — (496,815)— — 
Compensation Actually Paid to PEOs13,791,592 6,645,396 347,561 714,651 2,697,616 3,888,690 
(a)The fair values of time-based equity awards and performance-based restricted share units granted in 2020 are based on the closing price of the Company’s common shares as reported on the NASDAQ on the relevant valuation date. Performance-based restricted share units granted in 2021 were valued on the relevant valuation date using a Monte Carlo simulation model in accordance with the provisions of ASC Topic 718 using the following assumptions: (A) for valuations as of December 31, 2021, a risk free interest rate of 0.73% and share price volatility of 75.82%, for valuations on December 31, 2022, a risk free interest rate of 4.67% and share price volatility of 60.57%.” Note that the reference to valuations on December 31, 2022 is appropriate as this relates to the valuation of the 2021 PRUs as of December 31, 2022.
(b)Dr. Gagliano received, as part of her Interim CEO agreement, a sign-on equity grant consisting of $100,000 of fully vested shares (14,815 shares) and $670,000 of restricted stock units (99,259 restricted stock units) which vest in equal monthly installments beginning on April 30, 2022, subject to continued employment as Interim CEO. Dr. Gagliano vested in 24,815 units of the 99,259 restricted stock units granted prior to her resignation as Interim CEO in June 2022, and accordingly, 74,444 units of her restricted stock unit award were forfeited.
     
Non-PEO NEO Average Total Compensation Amount       $ 1,600,748 $ 1,457,621 $ 1,088,815 $ 1,601,825
Non-PEO NEO Average Compensation Actually Paid Amount       $ 2,390,906 $ 751,486 808,537 1,595,129
Adjustment to Non-PEO NEO Compensation Footnote         Represents amounts of average “compensation actually paid” as computed in accordance with Item 402(v) of Regulation S-K, not the actual average amount of compensation earned by or paid to the Company’s named executive officers, except for Dr. Tang with respect to fiscal years 2022, 2021, and 2020, Ms. Gagliano with respect to fiscal year 2022, and Ms. Eglinton Manner with respect to fiscal years 2023 and 2022. The table below reflects the adjustments made from the amounts reported in the “Total” column of the Summary Compensation Table for the named executive officers as a group (excluding Dr. Tang and Mses. Gagliano and Eglinton Manner, as applicable) each year to calculate the amounts set forth in “Compensation Actually Paid to non-PEO NEOs” column in the table above, using the same methodology as set forth in footnote 4, above.
NEO Averages
2023 ($)2022 ($)
2021 ($)(a)
2020 ($)(a)
Summary Compensation Table Total1,600,748 1,457,621 1,088,815 1,601,825 
Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year(712,288)(729,670)(552,646)(766,909)
Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year1,127,865 293,934 353,108 625,180 
Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years316,490 (102,310)43,223 59,438 
Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year— 85,437 29,005 80,708 
Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year58,090 (103,440)59,492 (5,113)
Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year— (150,086)(212,460)— 
Compensation Actually Paid to NEOs2,390,906 751,486 808,537 1,595,129 
(a)The fair values of time-based equity awards and performance-based restricted share units granted in 2020 are based on the closing price of the Company’s common shares as reported on the NASDAQ on the relevant valuation date. Performance-based restricted share units granted in 2021 were valued on the relevant valuation date using a Monte Carlo simulation model in accordance with the provisions of ASC Topic 718 using the following assumptions: (A) for valuations on December 31, 2021, a risk free interest rate of 0.73% and share price volatility of 75.82%. The fair value of non-qualified stock options granted to Ms. Gallagher as of December 31, 2021 were valued using a Black-Scholes model in accordance with the provision of ASC Topic 718 using the following assumptions: an expected term of 2 years, a risk-free interest rate of 0.73%, a dividend yield of 0% and share price volatility of 75.82%.
   
Compensation Actually Paid vs. Total Shareholder Return      
6762
     
Compensation Actually Paid vs. Net Income      
6764
     
Compensation Actually Paid vs. Company Selected Measure      
6766
     
Total Shareholder Return Vs Peer Group      
6762
     
Tabular List, Table      
Important Financial Performance Measures
Net Revenues
Adjusted Operating Income
Income Before Interest and Taxes
Stock Price
     
Total Shareholder Return Amount       $ 102.12 $ 60.02 108.22 131.82
Peer Group Total Shareholder Return Amount       106.34 99.31 125.43 130.04
Net Income (Loss)       $ 53,655,000 $ (17,934,000) $ (22,998,000) $ (14,922,000)
Company Selected Measure Amount       405,500,000 387,500,000 233,700,000 171,100,000
PEO Name Dr. Gagliano Dr. Tang Ms. Eglinton Manner Ms. Eglinton Manner   Dr. Tang Dr. Tang
Additional 402(v) Disclosure       For the relevant fiscal year, represents the cumulative total shareholder return (TSR) of OraSure Technologies, Inc. for the measurement periods ending on December 31 of each of 2023, 2022, 2021, and 2020, respectively. Reflects GAAP “Net Income (Loss)” in the Company’s Consolidated Statement of Operations included in the Company’s Annual Report on Form 10-K for each of the years ended December 31, 2023, 2022, 2021, and 2020. Represents “Net Revenues” in the Company’s Consolidated Statement of Operations included in the Company’s Annual Report on Form 10-K for each of the years ended December 31, 2023, 2022, 2021, and 2020.      
Measure:: 1              
Pay vs Performance Disclosure              
Name       Net Revenues      
Measure:: 2              
Pay vs Performance Disclosure              
Name       Adjusted Operating Income      
Measure:: 3              
Pay vs Performance Disclosure              
Name       Income Before Interest and Taxes      
Measure:: 4              
Pay vs Performance Disclosure              
Name       Stock Price      
Carrie Eglinton Manner [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount       $ 6,701,767 $ 6,746,923    
PEO Actually Paid Compensation Amount       13,791,592 6,645,396    
Nancy Gagliano, M.D. [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount         940,292    
PEO Actually Paid Compensation Amount         347,561    
Stephen S. Tang, Ph.D. [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount         2,769,508 $ 2,959,781 $ 3,085,421
PEO Actually Paid Compensation Amount         714,651 2,697,616 3,888,690
PEO | Carrie Eglinton Manner [Member] | Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       (4,873,637) (5,600,000)    
PEO | Carrie Eglinton Manner [Member] | Fair Value at Fiscal YearEnd of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       8,377,123 5,498,473    
PEO | Carrie Eglinton Manner [Member] | Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       3,488,559 0    
PEO | Carrie Eglinton Manner [Member] | Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       0 0    
PEO | Carrie Eglinton Manner [Member] | Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       97,780 0    
PEO | Carrie Eglinton Manner [Member] | Fair Value as of Prior Fiscal YearEnd of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       0 0    
PEO | Nancy Gagliano, M.D. [Member] | Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount         (770,000)    
PEO | Nancy Gagliano, M.D. [Member] | Fair Value at Fiscal YearEnd of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount         0    
PEO | Nancy Gagliano, M.D. [Member] | Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount         (40,879)    
PEO | Nancy Gagliano, M.D. [Member] | Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount         218,148    
PEO | Nancy Gagliano, M.D. [Member] | Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount         0    
PEO | Nancy Gagliano, M.D. [Member] | Fair Value as of Prior Fiscal YearEnd of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount         0    
PEO | Stephen S. Tang, Ph.D. [Member] | Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount         (834,913) (1,946,860) (1,218,000)
PEO | Stephen S. Tang, Ph.D. [Member] | Fair Value at Fiscal YearEnd of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount         0 1,337,758 1,799,376
PEO | Stephen S. Tang, Ph.D. [Member] | Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount         0 132,795 237,531
PEO | Stephen S. Tang, Ph.D. [Member] | Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount         664,350 0 0
PEO | Stephen S. Tang, Ph.D. [Member] | Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount         (1,387,479) 214,142 (15,638)
PEO | Stephen S. Tang, Ph.D. [Member] | Fair Value as of Prior Fiscal YearEnd of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount         (496,815) 0 0
Non-PEO NEO | Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       (712,288) (729,670) (552,646) (766,909)
Non-PEO NEO | Fair Value at Fiscal YearEnd of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       1,127,865 293,934 353,108 625,180
Non-PEO NEO | Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       316,490 (102,310) 43,223 59,438
Non-PEO NEO | Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       0 85,437 29,005 80,708
Non-PEO NEO | Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       58,090 (103,440) 59,492 (5,113)
Non-PEO NEO | Fair Value as of Prior Fiscal YearEnd of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year [Member]              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       $ 0 $ (150,086) $ (212,460) $ 0